Tumor necrosis factor inhibitors from poxviruses with an emphasis on tanapoxvirus-2L protein

Recent Patents on DNA and Gene Sequences

Volumn 5, Issue 2, 2011, Pages 97-103

  Jeng, David ^a   Rahman, Masmudur M ^b   McFadden, Grant ^b   Essani, Karim ^a  

^a WESTERN MICHIGAN UNIVERSITY   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Cytokines; Immune evasion; Inflammation; Poxvirus; Tumor necrosis factor; Viroceptors

Indexed keywords

ADALIMUMAB; ALPHA 2 MACROGLOBULIN; BETA 2 MICROGLOBULIN; CD30 LIGAND; CYTOKINE; ETANERCEPT; GAMMA INTERFERON; INFLIXIMAB; INTERLEUKIN 2; INTERLEUKIN 5; PROTEIN TPV 2L; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR BINDING PROTEIN; TUMOR NECROSIS FACTOR INHIBITOR; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG; VIRUS PROTEIN;

APOPTOSIS; ARTICLE; AUTOIMMUNE DISEASE; BINDING AFFINITY; CELL CYCLE ARREST; CONGESTIVE HEART FAILURE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DEMYELINATING DISEASE; DRUG HYPERSENSITIVITY; HUMAN; INFECTION; INFLAMMATORY DISEASE; LYMPHOMA; MACROPHAGE; NONHUMAN; NUCLEOTIDE SEQUENCE; POXVIRUS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN PURIFICATION; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION;

ALPHA-MACROGLOBULINS; BETA 2-MICROGLOBULIN; HUMANS; IMMUNE EVASION; MULTIPROTEIN COMPLEXES; POXVIRIDAE; PROTEIN BINDING; TUMOR NECROSIS FACTOR-ALPHA; VIRAL PROTEINS; YATAPOXVIRUS;

PEPPER GOLDEN MOSAIC VIRUS - [MEXICO]; POXVIRIDAE;

EID: 79959932581     PISSN: 18722156     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221511796392033     Document Type: Article

References (69)

1. Seet BT, Johnston JB, Brunetti CR, et al. Poxviruses and immune evasion. Annu Rev Immunol 2003; 21: 377-423.
2. Essani K, Chalasani S, Eversole R, Beuving L, Birmingham L. Multiple anti-cytokine activities secreted from tanapox virusinfected cells. Microb Pathog 1994; 17(5): 347-53.
3. Paulose M, Bennett BL, Manning AM, Essani K. Selective inhibition of TNF-alpha induced cell adhesion molecule gene expression by tanapox virus. Microb Pathog 1998; 25(1): 33-41.
4. Smith CA, Farrah T, Goodwin RG. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell 1994; 76(6): 959-62.
5. Hehlgans T, Pfeffer K. The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games. Immunology 2005; 115(1): 1-20.
6. Chan FK, Chun HJ, Zheng L, Siegel RM, Bui KL, Lenardo MJ. A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science 2000; 288(5475): 2351-54.
7. Siebert S, Fielding CA, Williams BD, Brennan P. Mutation of the extracellular domain of tumour necrosis factor receptor 1 causes reduced NF-kappaB activation due to decreased surface expression. FEBS Lett 2005; 579(23): 5193-8.
8. Lin J, Ziring D, Desai S, et al. TNFalpha blockade in human diseases: an overview of efficacy and safety. Clin Immunol 2008; 126(1): 13-30.
9. Mohler KM, Torrance DS, Smith CA, et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 1993; 151(3): 1548-61.
10. Harriman G, Harper LK, Schaible TF. Summary of clinical trials in rheumatoid arthritis using infliximab, an anti-TNFalpha treatment. Ann Rheum Dis 1999; 58 Suppl 1: I61-4.
11. Scheinfeld N. Adalimumab (HUMIRA): a review. J Drugs Dermatol 2003; 2(4): 375-7.
12. Wong M, Ziring D, Korin Y, et al. TNFalpha blockade in human diseases: mechanisms and future directions. Clin Immunol 2008; 126(2): 121-36.
13. Palladino MA, Bahjat FR, Theodorakis EA, Moldawer LL. Anti-TNF-alpha therapies: the next generation. Nat Rev Drug Discov 2003; 2(9): 736-46.
14. Rahman MM, McFadden G. Modulation of tumor necrosis factor by microbial pathogens. PLoS Pathog 2006; 2(2): e4.
15. Cunnion KM. Tumor necrosis factor receptors encoded by poxviruses. Mol Genet Metab 1999; 67(4): 278-82.
16. Xu X, Nash P, McFadden G. Myxoma virus expresses a TNF receptor homolog with two distinct functions. Virus Genes 2000; 21(1-2): 97-109.
17. Smith CA, Davis T, Wignall JM, et al. T2 open reading frame from the Shope fibroma virus encodes a soluble form of the TNF receptor. Biochem Biophys Res Commun 1991; 176(1): 335-42.
18. Smith CA, Smith TD, Smolak PJ, et al. Poxvirus genomes encode a secreted, soluble protein that preferentially inhibits beta chemokine activity yet lacks sequence homology to known chemokine receptors. Virology 1997; 236(2): 316-27.
19. Schreiber M, Rajarathnam K, McFadden G. Myxoma virus T2 protein, a tumor necrosis factor (TNF) receptor homolog, is secreted as a monomer and dimer that each bind rabbit TNFalpha, but the dimer is a more potent TNF inhibitor. J Biol Chem 1996; 271(23): 13333-41.
20. Upton C, Macen JL, Schreiber M, McFadden G. Myxoma virus expresses a secreted protein with homology to the tumor necrosis factor receptor gene family that contributes to viral virulence. Virology 1991; 184(1): 370-82.
21. Smith CA, Goodwin RG. Isolated viral protein TNF antagonists. US5464938, 1995.
22. Macen JL, Graham KA, Lee SF, Schreiber M, Boshkov LK, McFadden G. Expression of the myxoma virus tumor necrosis factor receptor homologue and M11L genes is required to prevent virus-induced apoptosis in infected rabbit T lymphocytes. Virology 1996; 218(1): 232-7.
23. Schreiber M, Sedger L, McFadden G. Distinct domains of M-T2, the myxoma virus tumor necrosis factor (TNF) receptor homolog, mediate extracellular TNF binding and intracellular apoptosis inhibition. J Virol 1997; 71(3): 2171-81.
24. Sedger L, McFadden G. M-T2: a poxvirus TNF receptor homologue with dual activities. Immunol Cell Biol 1996; 74(6): 538-45.
25. Hu FQ, Smith CA, Pickup DJ. Cowpox virus contains two copies of an early gene encoding a soluble secreted form of the type II TNF receptor. Virology 1994; 204(1): 343-56.
26. Smith CA, Hu FQ, Smith TD, et al. Cowpox virus genome encodes a second soluble homologue of cellular TNF receptors, distinct from CrmB, that binds TNF but not LT alpha. Virology 1996; 223(1): 132-47.
27. Loparev VN, Parsons JM, Knight JC, et al. A third distinct tumor necrosis factor receptor of orthopoxviruses. Proc Natl Acad Sci USA 1998; 95(7): 3786-91.
28. Saraiva M, Alcami A, Crm E, a novel soluble tumor necrosis factor receptor encoded by poxviruses. J Virol 2001; 75(1): 226-33.
29. Alejo A, Ruiz-Arguello MB, Ho Y, Smith VP, Saraiva M, Alcami A. A chemokine-binding domain in the tumor necrosis factor receptor from variola (smallpox) virus. Proc Natl Acad Sci USA 2006; 103(15): 5995-6000.
30. Pertejo AA, Herberg AA, Ruiz-arguello MB, Ho Y. Chemokine binding activity of viral tnf receptors and related proteins. US20090104178, 2009.
31. Reading PC, Khanna A, Smith GL. Vaccinia virus CrmE encodes a soluble and cell surface tumor necrosis factor receptor that contributes to virus virulence. Virology 2002; 292(2): 285-98.
32. Smith CA, Goodwin RG. Isolated poxvirus A53R-equivalent tumor necrosis factor antagonists. US5359039, 1994.
33. Panus JF. Cowpox virus encodes a fifth member of the tumor necrosis factor receptor family: A soluble, secreted CD30 homologue. Proc Natl Acad Sci USA 2002; 99(12): 8348-53.
34. Saraiva M, Smith P, Fallon PG, Alcami A. Inhibition of type 1 cytokine-mediated inflammation by a soluble CD30 homologue encoded by ectromelia (mousepox) virus. J Exp Med 2002; 196(6): 829-39.
35. Alcami A, Saraiva M. Viral CD30 polypeptide. US7186408, 2007.
36. Wiley SR, Goodwin RG, Smith CA. Reverse signaling via CD30 ligand. J Immunol 1996; 157(8): 3635-9.
37. Mcfadden G, Essani K. Nucleic acid molecules and polypeptides for immune modulation. US6894155, 2005.
38. McFadden G, Essani K. Nucleic acid molecules and polypeptides for immune modulation. US7585507, 2009.
39. Lee HJ, Essani K, Smith GL. The genome sequence of Yaba-like disease virus, a yatapoxvirus. Virology 2001; 281(2): 170-92.
40. Brunetti CR, Paulose MM, Singh R, et al. A secreted high-affinity inhibitor of human TNF from Tanapox virus. Proc Natl Acad Sci USA 2003; 100(8): 4831-6.
41. Afonso CL, Tulman ER, Lu Z, et al. The genome of swinepox virus. J Virol 2002; 76(2): 783-90.
42. Rahman MM, Barrett JW, Brouckaert P, McFadden G. Variation in ligand binding specificities of a novel class of poxvirus-encoded tumor necrosis factor-binding protein. J Biol Chem 2006; 281(32): 22517-26.
43. Rahman MM, Jeng D, Singh R, Coughlin J, Essani K, McFadden G. Interaction of human TNF and beta2-microglobulin with Tanapox virus-encoded TNF inhibitor, TPV-2L. Virology 2009; 386(2): 462-8.
44. Yang Z, West AP Jr, Bjorkman PJ. Crystal structure of TNFalpha complexed with a poxvirus MHC-related TNF binding protein. Nat Struct Mol Biol 2009; 16(11): 1189-91.
45. Steed PM, Tansey MG, Zalevsky J, et al. Inactivation of TNF signaling by rationally designed dominant-negative TNF variants. Science 2003; 301(5641): 1895-8.
46. Yang XD, Tisch R, Singer SM, et al. Effect of tumor necrosis factor alpha on insulin-dependent diabetes mellitus in NOD mice. I. The early development of autoimmunity and the diabetogenic process. J Exp Med 1994; 180(3): 995-1004.
47. Wang B, Andre I, Gonzalez A, et al. Interferon-gamma impacts at multiple points during the progression of autoimmune diabetes. Proc Natl Acad Sci USA 1997; 94(25): 13844-9.
48. Bending D, De La Pena H, Veldhoen M, et al. Highly purified Th17 cells from BDC2.5NOD mice convert into Th1-like cells in NOD/SCID recipient mice. J Clin Invest 2009; 119(3): 565-72.
49. Krams SM, Cao S, Hayashi M, Villanueva JC, Martinez OM. Elevations in IFN-γ, IL-5, and IL-10 in Patients with the Autoimmune Disease Primary Biliary Cirrhosis: Association with Autoantibodies and Soluble CD30. Clin Immunol Immunopathol 1996; 80(3): 311-20.
50. Armstrong PB, Quigley JP. Alpha2-macroglobulin: an evolutionarily conserved arm of the innate immune system. Dev Comp Immunol 1999; 23(4-5): 375-90.
51. Starkey PM, Barrett AJ. Inhibition by alpha-macroglobulin and other serum proteins. Biochem J 1973; 131(4): 823-31.
52. Strickland DK, Ashcom JD, Williams S, Burgess WH, Migliorini M, Argraves WS. Sequence identity between the alpha 2-macroglobulin receptor and low density lipoprotein receptor-related protein suggests that this molecule is a multifunctional receptor. J Biol Chem 1990; 265(29): 17401-4.
53. LaMarre J, Wollenberg GK, Gonias SL, Hayes MA. Cytokine binding and clearance properties of proteinase-activated alpha 2-macroglobulins. Lab Invest 1991; 65(1): 3-14.
54. Gonias SL, Pizzo SV. Chemical and structural modifications of alpha 2-macroglobulin: effects on receptor binding and endocytosis studied in an in vivo model. Ann NY Acad Sci 1983; 421: 457-71.
55. Feldman SR, Ney KA, Gonias SL, Pizzo SV. In vitro binding and in vivo clearance of human alpha 2-macroglobulin after reaction with endoproteases from four different classes. Biochem Biophys Res Commun 1983; 114(2): 757-62.
56. Sottrup-JL, Stepanik TM, Kristensen T, et al. Common evolutionary origin of alpha 2-macroglobulin and complement components C3 and C4. Proc Natl Acad Sci U S A 1985; 82(1): 9-13.
57. Crookston KP, Webb DJ, Wolf BB, Gonias SL. Classification of alpha 2-macroglobulin-cytokine interactions based on affinity of noncovalent association in solution under apparent equilibrium conditions. J Biol Chem 1994; 269(2): 1533-40.
58. Philip A, O'Connor MD. Interaction of transforming growth factorbeta 1 with alpha 2-macroglobulin. Role in transforming growth factor-beta 1 clearance. J Biol Chem 1991; 266(33): 22290-6.
59. Hall SW, LaMarre J, Marshall LB, Hayes MA, Gonias SL. Binding of transforming growth factor-beta 1 to methylamine-modified alpha 2-macroglobulin and to binary and ternary alpha 2-macroglobulin-proteinase complexes. Biochem J 1992; 281(Pt 2): 569-75.
60. Crookston KP, Webb DJ, Lamarre J, Gonias SL. Binding of platelet-derived growth factor-BB and transforming growth factor-beta 1 to alpha 2-macroglobulin in vitro and in vivo: comparison of receptor-recognized and non-recognized alpha 2-macroglobulin conformations. Biochem J 1993; 293(Pt 2): 443-50.
61. Gonias SL. Alpha 2-macroglobulin: a protein at the interface of fibrinolysis and cellular growth regulation. Exp Hematol 1992; 20(3): 302-311.
62. Borth W, Teodorescu M. Inactivation of human interleukin-2 (IL-2) by alpha 2-macroglobulin-trypsin complexes. Immunology 1986; 57(3): 367-71.
63. Wollenberg GK, LaMarre J, Rosendal S, Gonias SL, Hayes MA. Binding of tumor necrosis factor alpha to activated forms of human plasma alpha 2 macroglobulin. Am J Pathol 1991; 138(2): 265-72.
64. James K, van den Haan J, Lens S, Farmer K. Preliminary studies on the interaction of TNF alpha and IFN gamma with alpha 2-macroglobulin. Immunol Lett 1992; 32(1): 49-57.
65. Argiles A, Mourad G, Axelrud CC, Watrin A, Mion C, Cavadore JC. High-molecular-mass proteins in haemodialysis-associated amyloidosis. Clin Sci (Lond) 1989; 76(5): 547-52.
66. Gouin CA, Laune D, Granier C, et al. Alpha2-Macroglobulin, the main serum antiprotease, binds beta2-microglobulin, the light chain of the class I major histocompatibility complex, which is involved in human disease. Clin Sci (Lond) 2000; 98(4): 427-33.
67. Spriggs MK, Koller BH, Sato T, et al. Beta 2-microglobulin-, CD8+ T-cell-deficient mice survive inoculation with high doses of vaccinia virus and exhibit altered IgG responses. Proc Natl Acad Sci USA 1992; 89(13): 6070-4.
68. Kaymakcalan Z, Sakorafas P, Bose S, et al. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin Immunol 2009; 131(2): 308-16.
69. Alcami A, Khanna A, Paul NL, Smith GL. Vaccinia virus strains Lister, USSR and Evans express soluble and cell-surface tumour necrosis factor receptors. J Gen Virol 1999; 80(Pt 4): 949-59.